International Consensus on GLP-1 RA Safety in Pregnancy Released
A groundbreaking international consensus statement addresses the safety of GLP-1 receptor agonists during pregnancy, highlighting significant research gaps.
A new consensus statement emphasizes the need for more research on GLP-1 RAs in pregnant women, especially those with diabetes.
The statement includes recommendations for preconception and postpartum care, urging caution in GLP-1 RA use during pregnancy.
Findings suggest no increased risk for congenital anomalies with GLP-1 RA discontinuation in early pregnancy, but concerns remain regarding miscarriage rates.
An international consensus statement has been released to address the safety of GLP-1 receptor agonists (RAs) during pregnancy, particularly for women with diabetes. This initiative comes in response to the alarming lack of research on the implications of these medications for women of reproductive age. The statement was presented by Dr. Claire L. Meek from the Leicester Diabetes Centre at the recent European Association for the Study of Diabetes (EASD) 2026 Annual Meeting, aiming to guide clinical practices amidst significant uncertainties.
Historically, GLP-1 RAs have been widely used for managing diabetes, yet their safety during pregnancy remains inadequately studied. The consensus was formed by a panel of 33 international experts in obstetrics and diabetes, alongside input from 60 women with diabetes experiences. The report highlights the urgent need for enhanced research funding to address the estimated $70 billion market for these drugs, particularly in the context of women's health.
The consensus statement is part of a series published in The Lancet, emphasizing the necessity for robust studies on GLP-1 RAs. Despite the increasing prevalence of diabetes in pregnancy, current guidelines recommend their use primarily before conception and not during pregnancy. A meta-analysis conducted by Meek and colleagues reviewed studies involving nearly 50,000 reproductive-age women with diabetes, revealing only a limited number of studies that provided original safety data regarding GLP-1 RA use during pregnancy.
Key findings from the analysis indicate that discontinuing GLP-1 RAs in the first trimester does not correlate with an increased risk of congenital anomalies. However, there were concerns regarding miscarriage rates, with some studies suggesting a higher incidence among women exposed to GLP-1 RAs. The authors noted that these findings are difficult to interpret due to methodological limitations in the studies reviewed. Recommendations from the consensus include strong contraceptive measures during GLP-1 RA use and a cautious approach to medication discontinuation upon discovering a pregnancy.
Looking ahead, the consensus aims to improve clinical decision-making for women with diabetes considering pregnancy. It highlights the importance of counseling and planning for pregnancy, as well as the need for further research to clarify the safety of GLP-1 RAs during lactation. The call for more comprehensive studies is critical to ensure the health and safety of both mothers and their children in the context of diabetes management.
